Assignee
BYONDIS BV
NL·17 granted patents·7 pending applications·14 citations·filing 2016–2023
Top patents by PatentIndex Score
24 records- 0188US11104968B2Site-specific conjugation of linker drugs to antibodies and resulting ADCSBYONDIS BV·Filed 2019·Granted Aug 31, 2021·2 cites·16 claims
- 0288US10814009B2Selective reduction of cysteine-engineered antibodiesBYONDIS BV·Filed 2017·Granted Oct 27, 2020·4 cites·20 claims
- 0387US11584801B2Anti-5T4 antibodies and antibody-drug conjugatesBYONDIS BV·Filed 2021·Granted Feb 21, 2023·2 cites·20 claims
- 0486US11008400B2Anti-5T4 antibodies and antibody-drug conjugatesBYONDIS BV·Filed 2016·Granted May 18, 2021·5 cites·20 claims
- 0576US12180552B2Site-specific conjugation of linker drugs to antibodies and resulting ADCsBYONDIS BV·Filed 2021·Granted Dec 31, 2024·0 cites·19 claims
- 0674US12350345B2Dual conjugation process for preparing antibody-drug conjugatesBYONDIS BV·Filed 2023·Granted Jul 8, 2025·0 cites·21 claims
- 0772US11382982B2Duocarmycin ADCs showing improved in vivo antitumor activityBYONDIS BV·Filed 2019·Granted Jul 12, 2022·0 cites·10 claims
- 0871US11274159B2Anti-SIRPα antibodiesBYONDIS BV·Filed 2018·Granted Mar 15, 2022·1 cites·10 claims
- 0961US11718681B2Anti-SIRP α antibodiesBYONDIS BV·Filed 2022·Granted Aug 8, 2023·0 cites·23 claims
- 1060US2025136717A1Novel masked antibodiesBYONDIS BV·Filed 2023·Application pending·0 cites
- 1158US12180295B2Humanized anti-SIRPα antibodiesBYONDIS BV·Filed 2019·Granted Dec 31, 2024·0 cites·22 claims
- 1257US11696958B2Dual conjugation process for preparing antibody-drug conjugatesBYONDIS BV·Filed 2018·Granted Jul 11, 2023·0 cites·18 claims
- 1357US2023144211A1Antifolate linker-drugs and antibody-drug conjugatesBYONDIS BV·Filed 2022·Application pending·0 cites
- 1456US2025114466A1Antifolate linker-drugs and antibody-drug conjugatesBYONDIS BV·Filed 2022·Application pending·0 cites
- 1554US11633492B2Process for the synthesis of linker-drug vc-seco-DUBABYONDIS BV·Filed 2018·Granted Apr 25, 2023·0 cites·16 claims
- 1653US2022119392A1Antifolate linker-drugs and antibody-drug conjugatesBYONDIS BV·Filed 2021·Application pending·0 cites
- 1753US2024261426A1Conjugates comprising phosphoantigens and their use in therapyBYONDIS BV·Filed 2022·Application pending·0 cites
- 1852US2024376214A1Anti-c-met antibodies and antibody-drug conjugatesBYONDIS BV·Filed 2022·Application pending·0 cites
- 1951US2023092648A1Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfateBYONDIS BV·Filed 2021·Application pending·0 cites
- 2048US11419944B2Non-linear self-immolative linkers and conjugates thereofBYONDIS BV·Filed 2017·Granted Aug 23, 2022·0 cites·20 claims
- 2147US10815194B2Process for the preparation of mono-protected α,ω-diamino alkanesBYONDIS BV·Filed 2017·Granted Oct 27, 2020·0 cites·20 claims
- 2236US12178881B2Filterable duocarmycin-containing antibody-drug conjugate compositions and related methodsBYONDIS BV·Filed 2019·Granted Dec 31, 2024·0 cites·15 claims
- 2336US11077204B2Compositions comprising antibody-duocarmycin drug conjugatesBYONDIS BV·Filed 2016·Granted Aug 3, 2021·0 cites·25 claims
- 2436US10821191B2SYD985 treatment of T-DM1 refractory cancer patientsBYONDIS BV·Filed 2016·Granted Nov 3, 2020·0 cites·14 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →